Friedrich Von Loe

📢 Pentixapharm AG Acquires Target Discovery Business of Glycotope GmbH, effective July 1st.  This strategic acquisition of the Berlin-based biotech company marks a significant milestone in their mission to develop novel targeted radiopharmaceuticals against a broad range of malignancies. 🌟 𝗞𝗲𝘆 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 𝗼𝗳 𝘁𝗵𝗲 𝗔𝗰𝗾𝘂𝗶𝘀𝗶𝘁𝗶𝗼𝗻: • 𝗖𝗼𝗺𝗽𝗿𝗲𝗵𝗲𝗻𝘀𝗶𝘃𝗲 𝗣𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼: The deal includes a portfolio of 𝗽𝗿𝗲𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗮𝗻𝘁𝗶𝗯𝗼𝗱𝗶𝗲𝘀 against multiple oncology targets, 𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗼𝗿𝗶𝗲𝘀, cell banks, a 𝘁𝘂𝗺𝗼𝗿 𝘁𝗮𝗿𝗴𝗲𝘁 𝗱𝗮𝘁𝗮𝗯𝗮𝘀𝗲, and essential equipment.    • 𝗘𝗻𝗵𝗮𝗻𝗰𝗲𝗱 𝗜𝗻𝘁𝗲𝗹𝗹𝗲𝗰𝘁𝘂𝗮𝗹 𝗣𝗿𝗼𝗽𝗲𝗿𝘁𝘆: This acquisition broadens the 𝗜𝗣 𝗽𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼 beyond the CXCR4 receptor, 𝗱𝗼𝘂𝗯𝗹𝗶𝗻𝗴 the 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗽𝗶𝗽𝗲𝗹𝗶𝗻𝗲 and expanding business and clinical opportunities.    • 𝗘𝘅𝗽𝗲𝗿𝘁 𝗧𝗲𝗮𝗺: Pentixapharm welcomes an 𝗶𝗻𝘁𝗲𝗴𝗿𝗮𝘁𝗲𝗱 𝘁𝗲𝗮𝗺 𝗼𝗳 𝟰𝟬 seasoned executives, R&D specialists, and administrators from Glycotope.    • 𝗟𝗲𝗮𝗱𝗲𝗿𝘀𝗵𝗶𝗽 𝗘𝘅𝗽𝗮𝗻𝘀𝗶𝗼𝗻: Patrik Kehler, former CSO of Glycotope, will join as Pentixapharm's 𝗖𝗦𝗢, and Henner Kollenberg, former CEO of Glycotope, will become the 𝗖𝗵𝗶𝗲𝗳 𝗕𝘂𝘀𝗶𝗻𝗲𝘀𝘀 𝗢𝗳𝗳𝗶𝗰𝗲𝗿.    💬 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝗳𝗿𝗼𝗺 𝗣𝗲𝗻𝘁𝗶𝘅𝗮𝗽𝗵𝗮𝗿𝗺'𝘀 𝗟𝗲𝗮𝗱𝗲𝗿𝘀: “Glycotope’s pipeline comprises 𝘀𝗲𝘃𝗲𝗿𝗮𝗹 𝗰𝗮𝗻𝗱𝗶𝗱𝗮𝘁𝗲𝘀 that can be 𝘂𝘀𝗲𝗱 𝗶𝗺𝗺𝗲𝗱𝗶𝗮𝘁𝗲𝗹𝘆 for 𝗽𝗿𝗼𝗼𝗳-𝗼𝗳-𝗰𝗼𝗻𝗰𝗲𝗽𝘁 𝘀𝘁𝘂𝗱𝗶𝗲𝘀 as next generation radiopharmaceuticals,” said Dr. Hakim Bouterfa, CEO of Pentixapharm AG. “We look forward to 𝗺𝗮𝘅𝗶𝗺𝗶𝘇𝗶𝗻𝗴 𝘁𝗵𝗲 𝘀𝘆𝗻𝗲𝗿𝗴𝘆 of Pentixapharm’s know-how and Glycotope’s target discovery for the 𝗯𝗲𝗻𝗲𝗳𝗶𝘁 𝗼𝗳 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 in both diagnostics and therapeutic applications.” “The transaction 𝘀𝘁𝗿𝗲𝗻𝗴𝘁𝗵𝗲𝗻𝘀 our 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗽𝗶𝗽𝗲𝗹𝗶𝗻𝗲 and administrative capacities, facilitating a 𝘀𝗲𝗮𝗺𝗹𝗲𝘀𝘀 𝘁𝗿𝗮𝗻𝘀𝗶𝘁𝗶𝗼𝗻 to the 𝗙𝗿𝗮𝗻𝗸𝗳𝘂𝗿𝘁 𝗦𝘁𝗼𝗰𝗸 𝗘𝘅𝗰𝗵𝗮𝗻𝗴𝗲,” noted 𝗗𝗿. 𝗔𝗻𝗱𝗿𝗲𝗮𝘀 𝗘𝗰𝗸𝗲𝗿𝘁, Chairman of the Supervisory Board of both Pentixapharm and Eckert & Ziegler SE. This acquisition positions Pentixapharm to develop 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝗿𝗮𝗱𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹𝘀 by leveraging Glycotope’s 𝘂𝗻𝗶𝗾𝘂𝗲 𝗚𝗹𝘆𝗰𝗼𝗧𝗮𝗿𝗴𝗲𝘁𝘀—tumor-associated 𝗰𝗮𝗿𝗯𝗼𝗵𝘆𝗱𝗿𝗮𝘁𝗲 𝘀𝘁𝗿𝘂𝗰𝘁𝘂𝗿𝗲𝘀 with 𝘀𝘂𝗽𝗲𝗿𝗶𝗼𝗿 𝘁𝘂𝗺𝗼𝗿-𝘀𝗽𝗲𝗰𝗶𝗳𝗶𝗰𝗶𝘁𝘆. These advancements have the potential to close the treatment gap for many solid tumors, enhancing both diagnostic and therapeutic applications. 🔗 Learn More: https://lnkd.in/eCXh35Nw #NuclearMedicine #Radiopharmaceuticals #Acquisition #PrecisionMedicine  

106

🔬 Big news for the #LifeSciences ecosystem in Barcelona-Catalonia! 🧪The German biotech QIAGEN is set to invest €13 million over the next five years to expand its facilities in Barcelona. 🥼This investment will create a global innovation center dedicated to advancing molecular diagnostics for infectious diseases, opening in early 2026. Over 400 high-value jobs are expected to be generated in the long term. 🤝This initiative is supported by Catalonia Trade & Investment. We help companies establish themselves in #Catalonia and offer continuous support for their operations! Read the news👇 https://lnkd.in/dcBztBiB #Barcelona #Innovation #Biotechnology #Healthcare #LifeSciences

36

2 Kommentare

+++ 𝗤𝟭 𝗿𝗲𝘀𝘂𝗹𝘁𝘀 𝟮𝟬𝟮𝟰 𝗮𝗻𝗱 𝗰𝗼𝗿𝗽𝗼𝗿𝗮𝘁𝗲 𝘂𝗽𝗱𝗮𝘁𝗲 +++ We started the year with good progress across our oncology pipeline and our commercialization activities. Some key events: 🔬 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆: We and our collaboration partner Duality Biologics dosed the first patient in a Phase 3 clinical trial with our #ADC candidate BNT323/DB-1303 in breast cancer patients, advancing towards BioNTech’s goal of ten or more potentially registrational trials running by the end of 2024. 🩹 𝗖𝗢𝗩𝗜𝗗-𝟭𝟵: We are focusing on preparing for variant-strain adaptation of our COVID-19 vaccine to be ready for a commercial launch ahead of the upcoming 2024/2025 vaccination season, pending approvals. 🌎 𝗖𝗼𝗺𝗺𝗲𝗿𝗰𝗶𝗮𝗹 𝗿𝗲𝗮𝗱𝗶𝗻𝗲𝘀𝘀: We appointed our General Manager Fatma Ocak for the U.S. in line with our commercial preparations to drive our first expected global #oncology product launch. 𝗟𝗶𝗻𝗸 𝘁𝗼 𝗣𝗥 𝗮𝗻𝗱 𝗳𝗼𝗿𝘄𝗮𝗿𝗱-𝗹𝗼𝗼𝗸𝗶𝗻𝗴 𝘀𝘁𝗮𝘁𝗲𝗺𝗲𝗻𝘁𝘀: https://lnkd.in/ePDQiHbH  

550

2 Kommentare

Key discussions emerged from the Veeva R&D Summit at the Marriott Madrid Auditorium, where Novo Nordisk's senior vice president, Thomas Senderovitz, emphasized the critical need for pharmaceutical companies to be involved in shaping AI regulations. Alongside James Weatherall from AstraZeneca, Senderovitz highlighted the necessity of harmonizing global AI regulations to facilitate uniform drug trials across different regions. Key Points: 🔹 Advocacy for increased pharma involvement in AI regulation 🔹 Challenges posed by disparate global regulatory systems 🔹 Anticipation of the FDA’s forthcoming AI guidance and the need for updates in Europe 🔹 Novo Nordisk’s advancements in AI, including the development of the AI super-computer Gefion Read more on this drive to establish unified global standards, ensuring more efficient and effective AI-driven research and innovation within the healthcare sector. https://lnkd.in/dffUNFcY #VeevaSummit #PharmaAI #NovoNordisk #AIRegulation #HealthcareInnovation #GlobalStandards

1

Yesterday, at our Arzneimittelforum, we were privileged to host Swantje Winkler, Senior Preclinical Manager at AOP Health Orphan Pharmaceuticals GmbH. She delivered an insightful talk on 'Toxicology in Drug Development'. Dr. Winkler illuminated the pivotal role of toxicological studies, emphasizing their significance not only in preclinical stages but also in phases 1-3 of clinical trials. Understanding the intricacies of toxicology is crucial in ensuring the safety and efficacy of pharmaceuticals throughout their development journey. A truly enlightening session! #clinicalpharmacology #DrugDevelopment #Toxicology #research #pharmaceuticals #clinicalstudies #learning

30

𝗤𝗨𝗔𝗡𝗧𝗥𝗢 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝗿𝗲𝗮𝗰𝗵𝗲𝘀 𝗮 𝗺𝗶𝗹𝗲𝘀𝘁𝗼𝗻𝗲 𝗶𝗻 𝘁𝗵𝗲 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻 𝘄𝗶𝘁𝗵 𝗕𝗼𝗲𝗵𝗿𝗶𝗻𝗴𝗲𝗿 𝗜𝗻𝗴𝗲𝗹𝗵𝗲𝗶𝗺 𝘁𝗼 𝗱𝗲𝘃𝗲𝗹𝗼𝗽 𝗳𝗶𝗿𝘀𝘁-𝗶𝗻-𝗰𝗹𝗮𝘀𝘀 #𝗰𝗮𝗻𝗰𝗲𝗿 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀: QUANTRO Therapeutics GmbH, a Spin-out from the research institutes IMBA and IMP in Vienna, announced that the company has reached a key milestone in its joint R&D program with Boehringer Ingelheim. In successfully applying QUANTRO’s proprietary QUANTROseq® Transcriptional Fingerprint technology, all pre-set goals for technical proof-of-concept, cross-validation of HTS screening technology and identification of high-quality hits for a previously undruggable transcription factor were fully accomplished. For many cancer patients there are no or only limited treatment options, which is why cancer remains to be a leading cause of death worldwide, accounting for nearly one in six deaths. Transcription factors have emerged as a promising class of therapeutic targets to address currently undruggable cancers. Transcription factors are central regulators of gene expression that are commonly dysregulated in cancer and have remained largely unamenable to pharmacological intervention. The joint R&D program, which was initiated in 2022, aims at changing the implied status quo via development of transformational, first-in-class cancer treatments. 𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲: https://lnkd.in/ehQ6Nvsb Michael Bauer, Ph.D., Norbert Kraut

2

𝐒𝐩𝐚𝐢𝐧'𝐬 𝐏𝐡𝐚𝐫𝐦𝐚 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞: 𝐆𝐫𝐨𝐰𝐭𝐡 & 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 Explore Spain's dynamic pharmaceutical market, where opportunities abound and innovation flourishes! Did you know? Spain boasts the 4th largest pharmaceutical market in #Europe by revenue and ranks 9th on the global scale, signifying its pivotal role in the industry's landscape. Our comprehensive infographic explores the regulatory framework, market overview, and prominent stakeholders shaping Spain's pharmaceutical sector. #spain #pharmaceutical #pharma #healthcare #insights10

13

How will Spain’s push for drug price transparency affect the pharma industry and the Spanish National Health System? In our most recent blog, our experts provide insights on the potential impacts, challenges, and what it means for future access to pharma innovations. Read more here: skp.link/mxf #BetterMarketAccess #Pharma #Healthcare #Innovation #SimonKucher

29

M&A in the pharma sector 💊      Boehringer Ingelheim, a major German biopharmaceutical company focused on animal and human health, has acquired Nerio Therapeutics for $1.3B.    Boehringer is a key player in the pharma space and is active in-terms of corporate developments. A brief summary of a few key recent events: • The acquisition of Nerio Therapeutics provides Boehringer with a strong preclinical development pipeline, particularly for the immuno-oncology therapeutic area.   • Boehringer announced an ambitious pipeline strategy, which aims to launch 25 new treatments by 2030, focusing on mid-stage and late-stage trials over the next 12 to 18 months. This is predominately in mental health, oncology, cardiovascular, renal, and metabolic diseases.  • Boehringer has a history of using inorganic growth to enhance their immune-modulating therapy platforms, including the CHF 450 million purchase of Swiss biotech T3 Pharmaceuticals AG in November 2023.    This is one of many strategic deals we’re tracking in the pharmaceutical space.    Stay updated on more significant deals like this one every week in our chemical tracker: https://lnkd.in/eqkaV4zS    #PharmaTrends #MergersAndAcquisitions #PharmaInnovation #StrategicGrowth 

8

C-suite leaders from Eli Lilly and Company, Roche and Johnson & Johnson spoke at a Citeline-sponsored panel at Swiss Biotech Day in Basel and offered encouragement to start-ups trying to negotiate the tricky financial landscape. Biotech financing has been under pressure for a couple of years, forcing companies to work harder to advance their pipelines. Forging partnerships with big pharma is more important than ever, and this article provides biotech leaders with insider pointers on how to approach this. Access it now: https://ow.ly/rRZY50RxheT. #BiotechLeaders #PharmaPartnerships #BiotechFinancing #HealthcareInnovation #CLevelPanel #SwissBiotechDay

2

C-suite leaders from Eli Lilly and Company, Roche and Johnson & Johnson spoke at a Citeline-sponsored panel at Swiss Biotech Day in Basel and offered encouragement to start-ups trying to negotiate the tricky financial landscape. Biotech financing has been under pressure for a couple of years, forcing companies to work harder to advance their pipelines. Forging partnerships with big pharma is more important than ever, and this article provides biotech leaders with insider pointers on how to approach this. Access it now: https://ow.ly/QApL50RxhgF. #BiotechLeaders #PharmaPartnerships #BiotechFinancing #HealthcareInnovation #CLevelPanel #SwissBiotechDay

3

#PortfolioHighlights This month we continue to discuss the investment rationale behind the constituents of our #portfolio and share our views on the major #BigPharma companies. Novartis remains one of the industry leaders in #oncology and maintains its position among the 10 largest Big Pharma companies in 2023, with a capitalization of almost $207 billion. The company’s pipeline is not limited to the oncology sector; it also holds a diversified portfolio in immunology, neuroscience, cardiovascular, renal, and metabolic areas, with more than 20 key submissions in core therapeutic areas by 2028 (5 developments at the registration stage and 39 projects in Phase 3). The company has uplifted its full-year financial guidance based on 1Q24 revenue results, which have exceeded estimates for two blockbuster drugs: #Cosentyx, for inflammatory conditions, and #Entresto, for heart failure treatment. Current positive momentum also contributes to a +5% CAGR for sales during 2023-2028. Novartis actively participates in M&A activity, with the recent acquisition of #Arnivas to advance an oral protein degrader for prostate cancer, Pluvicto, and a deal with #Morphosys, which will strengthen its pipeline in oncology. We maintain our exposure to the company and have strong belief in its diversified #pipeline, which will allow it to strengthen its position in the expanding oncology market. Cosentyx, Entresto, Kesimpta, Pluvicto, Scemblix, Zolgensma, Kisqali, and Leqvio should fuel growth through 2030 and beyond. The company is currently traded at a slight discount to the sector and the market as a whole (forward P/E of 15x vs 16.6x for Big Cap Drug Average). Marketing | Capital at risk | For professional investors

3

Busy days at ESMO - European Society for Medical Oncology 2024 in Barcelona. Today, the BioInvent team presents a Trial in Progress poster for the company’s second anti-TNFR2 antibody, BI-1910. BI-1910 is currently enrolling patients in the monotherapy cohort of the Phase 1/2a study in patients with advanced solid tumors. The fifth planned dose level has been reached without any notable adverse events observed. The prespecified target dose range with robust target occupancy has been reached, and evidence of immune activation has been observed. Dose escalation will continue for exploration of a wide range of dose-safety/tolerability margin, and is expected to complete before year-end 2024, leading to opening Phase 2a with BI-1910 monotherapy in NSCLC in H1 2025. Phase 1 Part B dose escalation of BI-1910 in combination with pembrolizumab is expected to commence Q4 2024. Read the full poster: https://lnkd.in/eTih9uD4). #immunooncology #immunotherapy #antibodytherapeutics #biotechnology #lifescience

82

🚀 Calling All Life Sciences Experts: We Need Your Expertise! Dear LinkedIn Community, We are thrilled to announce a significant new study and are actively seeking distinguished experts in the life sciences field to contribute their insights. If you or someone you know has deep expertise in areas such as: · Biotech Research Scientist · Clinical Research Coordinator · Regulatory Affairs Specialist · Pharmaceutical Development Expert · Medical Science Liaison · Biometrics Specialist We would be grateful for your participation or recommendations. Your insights will be crucial in enhancing the depth and quality of our research, ultimately contributing to better healthcare outcomes. Here’s how you can get involved: 1. Self-Nominate: If you have relevant expertise and are interested in participating, please reach out to me directly at [email protected] 2. Nominate Others: If you know someone who fits the bill, kindly tag them or send me a message to facilitate an introduction. This is a great chance to be part of a transformative study and explore future collaboration possibilities. Thank you for your support, and I look forward to connecting with you! Kind regards,   Kevin B Global Operations Manager MedTech Surveys Panel Email: [email protected] Website: www.medtechsurveys.com #LifeSciences #Pharmaceuticals #ClinicalResearch #Biotechnology #ExpertConsultation #HealthcareResearch #BiotechResearch #MedicalScience

1

Novartis (NVS) kicked off 2024 with 1Q sales growth of 11% and core operating income expansion of +22%. Core margin hit a high of 38.4%, edging closer to the 2027 target of 40%. Portfolio constituents, including Entresto, Cosentyx, and Kesimpta, grew across the U.S., Europe, and China. Management discussed innovation milestones, including the launch of Fabhalta in Europe and developments for Scemblix and Pluvicto. Novartis' pipeline is benefitting from multiple submissions, while management is also focused on capital allocation strategies amidst strategic acquisitions to bolster oncology offerings. Novartis boosted its full-year guidance. The call also highlighted several risks: 1/ Patent expiration: The potential generic entry for Entresto in mid-2025 poses a risk to sales growth. 2/ Regulatory challenges: The planned filing for Kisqali (early breast cancer) may face delays due to manufacturing adjustments, which could impact the expected timeline for regulatory review. 3/ Competitive landscape: Competition in the IgA nephropathy (IgAN) market was mentioned, indicating potential challenges from other companies entering this space with similar treatments. 4/ Market dynamics: The slow initial uptake of Scemblix in the CML market, particularly for patients currently on imatinib, may indicate resistance to change from some physicians and patients. Want to learn more about 1Q Earnings? See us at https://lnkd.in/gaMqAd8r

1

nerai bio receives CHF 150’000 to release the full potential of genome editing. https://lnkd.in/d58MQsVf   Congratulations to amazing team of founders: Sasha M., Kim Fabiano Marquart, Lukas Schmidheini, Gerald Schwank, and Vincent Forster About: CRISPR is a revolutionary technology that enables gene editing therapies for inherited diseases. It uses proteins programmed with an RNA template to locate and correct disease-causing mutations in the genome. However, current CRISPR proteins have limitations in applicability, efficiency, and safety. The company builds on years of R&D in directed evolution, lab automation, and machine learning to develop an AI-driven high-throughput protein discovery platform. These engineered proteins will be licensed to gene therapy companies, tapping into a $4.4B market (2023, 78% YoY growth). The research team from University of Zurich has already developed parts of this platform, with findings published in leading journals. #SwissStartups #VentureKick

255

8 Kommentare

Mainz BioMed (@mainzbio), a biotech firm specializing in clinical laboratory tests, is making strides in early disease detection and prevention. According to Bill Caragol, the company's CFO, their genetic and genomic tests can reveal patients' unique genetic profiles, enabling doctors to tailor treatments more effectively and ushering in an era of personalized medicine. Caragol recently shared promising data from recent trials, highlighting the potential of their tests to detect cancer and chronic conditions at an early stage. Early detection is crucial, as it allows patients to receive timely treatment and improve their chances of survival. As diagnostic technology advances, Mainz BioMed aims to save lives and reduce healthcare costs through early disease identification. Their innovative approach could revolutionize how we approach cancer and chronic condition management. #biotechnology #cancerprevention #personalmedicine

1

We are thrilled that Dr. Alfredo J Lucendo Villarin presented clinical data from our ACESO Phase II study at UEG - United European Gastroenterology Week 2024 in Vienna. The results show that ESO-101 achieved a statistically significant reduction in peak eosinophil count (p=0.0318) compared to placebo for the treatment of eosinophilic esophagitis (EoE). This is exciting progress in addressing this challenging condition.   📄 Presentation title: "A novel delivery system for topical esophagitis treatment with mometasone furoate: results of the phase 2, randomized, double-blind, placebo-controlled ACESO trial" Read the abstract here: https://bit.ly/3Uz7j43   Read the press release here: https://bit.ly/4eM6Zqo

23